Global Duchenne Muscular Dystrophy Therapeutics Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Duchenne Muscular Dystrophy Therapeutics market size was valued at US$ 1300.3 million in 2023. With growing demand in downstream market, the Duchenne Muscular Dystrophy Therapeutics is forecast to a readjusted size of US$ 5197.3 million by 2030 with a CAGR of 21.9% during review period.
The research report highlights the growth potential of the global Duchenne Muscular Dystrophy Therapeutics market. Duchenne Muscular Dystrophy Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Duchenne Muscular Dystrophy Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Duchenne Muscular Dystrophy Therapeutics market.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Duchenne Muscular Dystrophy Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Duchenne Muscular Dystrophy Therapeutics market. It may include historical data, market segmentation by Type (e.g., Pain Management Drugs, Corticosteroids), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Duchenne Muscular Dystrophy Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Duchenne Muscular Dystrophy Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Duchenne Muscular Dystrophy Therapeutics industry. This include advancements in Duchenne Muscular Dystrophy Therapeutics technology, Duchenne Muscular Dystrophy Therapeutics new entrants, Duchenne Muscular Dystrophy Therapeutics new investment, and other innovations that are shaping the future of Duchenne Muscular Dystrophy Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Duchenne Muscular Dystrophy Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Duchenne Muscular Dystrophy Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Duchenne Muscular Dystrophy Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Duchenne Muscular Dystrophy Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Duchenne Muscular Dystrophy Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Duchenne Muscular Dystrophy Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Duchenne Muscular Dystrophy Therapeutics market.
Market Segmentation:
Duchenne Muscular Dystrophy Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Duchenne Muscular Dystrophy Therapeutics market size was valued at US$ 1300.3 million in 2023. With growing demand in downstream market, the Duchenne Muscular Dystrophy Therapeutics is forecast to a readjusted size of US$ 5197.3 million by 2030 with a CAGR of 21.9% during review period.
The research report highlights the growth potential of the global Duchenne Muscular Dystrophy Therapeutics market. Duchenne Muscular Dystrophy Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Duchenne Muscular Dystrophy Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Duchenne Muscular Dystrophy Therapeutics market.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Duchenne Muscular Dystrophy Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Duchenne Muscular Dystrophy Therapeutics market. It may include historical data, market segmentation by Type (e.g., Pain Management Drugs, Corticosteroids), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Duchenne Muscular Dystrophy Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Duchenne Muscular Dystrophy Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Duchenne Muscular Dystrophy Therapeutics industry. This include advancements in Duchenne Muscular Dystrophy Therapeutics technology, Duchenne Muscular Dystrophy Therapeutics new entrants, Duchenne Muscular Dystrophy Therapeutics new investment, and other innovations that are shaping the future of Duchenne Muscular Dystrophy Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Duchenne Muscular Dystrophy Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Duchenne Muscular Dystrophy Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Duchenne Muscular Dystrophy Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Duchenne Muscular Dystrophy Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Duchenne Muscular Dystrophy Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Duchenne Muscular Dystrophy Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Duchenne Muscular Dystrophy Therapeutics market.
Market Segmentation:
Duchenne Muscular Dystrophy Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Pain Management Drugs
- Corticosteroids
- Prednisolone
- Prednisone
- Deflazacort
- Hospitals
- Clinics
- Home Care
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Bristol-Myers Squibb
- FibroGen (US)
- Italfarmaco (Italy)
- Marathon
- NS Pharma (US)
- PTC Therapeutics (US)
- Pfizer
- ReveraGen BioPharma (US)
- Santhera Pharmaceuticals (Switzerland)
- Sarepta Therapeutics (US)
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2030
2.1.2 Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Duchenne Muscular Dystrophy Therapeutics Segment by Type
2.2.1 Pain Management Drugs
2.2.2 Corticosteroids
2.2.3 Prednisolone
2.2.4 Prednisone
2.2.5 Deflazacort
2.3 Duchenne Muscular Dystrophy Therapeutics Market Size by Type
2.3.1 Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Duchenne Muscular Dystrophy Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Duchenne Muscular Dystrophy Therapeutics Market Size by Application
2.5.1 Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
3 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Players
3.1.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS BY REGIONS
4.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Duchenne Muscular Dystrophy Therapeutics Market Size Growth (2019-2024)
4.3 APAC Duchenne Muscular Dystrophy Therapeutics Market Size Growth (2019-2024)
4.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024)
5.2 Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024)
5.3 Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2019-2024)
6.2 APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024)
6.3 APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Duchenne Muscular Dystrophy Therapeutics by Country (2019-2024)
7.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024)
7.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET FORECAST
10.1 Global Duchenne Muscular Dystrophy Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Duchenne Muscular Dystrophy Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Duchenne Muscular Dystrophy Therapeutics Forecast
10.1.3 APAC Duchenne Muscular Dystrophy Therapeutics Forecast
10.1.4 Europe Duchenne Muscular Dystrophy Therapeutics Forecast
10.1.5 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Forecast
10.2 Americas Duchenne Muscular Dystrophy Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.2.2 Canada Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.2.3 Mexico Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.2.4 Brazil Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3 APAC Duchenne Muscular Dystrophy Therapeutics Forecast by Region (2025-2030)
10.3.1 China Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.2 Japan Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.3 Korea Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.4 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.5 India Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.6 Australia Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4 Europe Duchenne Muscular Dystrophy Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4.2 France Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4.3 UK Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4.4 Italy Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4.5 Russia Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5.2 South Africa Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5.3 Israel Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5.4 Turkey Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5.5 GCC Countries Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.6 Global Duchenne Muscular Dystrophy Therapeutics Forecast by Type (2025-2030)
10.7 Global Duchenne Muscular Dystrophy Therapeutics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Offered
11.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bristol-Myers Squibb Main Business Overview
11.1.5 Bristol-Myers Squibb Latest Developments
11.2 FibroGen (US)
11.2.1 FibroGen (US) Company Information
11.2.2 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 FibroGen (US) Main Business Overview
11.2.5 FibroGen (US) Latest Developments
11.3 Italfarmaco (Italy)
11.3.1 Italfarmaco (Italy) Company Information
11.3.2 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Italfarmaco (Italy) Main Business Overview
11.3.5 Italfarmaco (Italy) Latest Developments
11.4 Marathon
11.4.1 Marathon Company Information
11.4.2 Marathon Duchenne Muscular Dystrophy Therapeutics Product Offered
11.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Marathon Main Business Overview
11.4.5 Marathon Latest Developments
11.5 NS Pharma (US)
11.5.1 NS Pharma (US) Company Information
11.5.2 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 NS Pharma (US) Main Business Overview
11.5.5 NS Pharma (US) Latest Developments
11.6 PTC Therapeutics (US)
11.6.1 PTC Therapeutics (US) Company Information
11.6.2 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 PTC Therapeutics (US) Main Business Overview
11.6.5 PTC Therapeutics (US) Latest Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Duchenne Muscular Dystrophy Therapeutics Product Offered
11.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Pfizer Main Business Overview
11.7.5 Pfizer Latest Developments
11.8 ReveraGen BioPharma (US)
11.8.1 ReveraGen BioPharma (US) Company Information
11.8.2 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 ReveraGen BioPharma (US) Main Business Overview
11.8.5 ReveraGen BioPharma (US) Latest Developments
11.9 Santhera Pharmaceuticals (Switzerland)
11.9.1 Santhera Pharmaceuticals (Switzerland) Company Information
11.9.2 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Santhera Pharmaceuticals (Switzerland) Main Business Overview
11.9.5 Santhera Pharmaceuticals (Switzerland) Latest Developments
11.10 Sarepta Therapeutics (US)
11.10.1 Sarepta Therapeutics (US) Company Information
11.10.2 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Sarepta Therapeutics (US) Main Business Overview
11.10.5 Sarepta Therapeutics (US) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2030
2.1.2 Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Duchenne Muscular Dystrophy Therapeutics Segment by Type
2.2.1 Pain Management Drugs
2.2.2 Corticosteroids
2.2.3 Prednisolone
2.2.4 Prednisone
2.2.5 Deflazacort
2.3 Duchenne Muscular Dystrophy Therapeutics Market Size by Type
2.3.1 Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Duchenne Muscular Dystrophy Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Home Care
2.5 Duchenne Muscular Dystrophy Therapeutics Market Size by Application
2.5.1 Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
3 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Players
3.1.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS BY REGIONS
4.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Duchenne Muscular Dystrophy Therapeutics Market Size Growth (2019-2024)
4.3 APAC Duchenne Muscular Dystrophy Therapeutics Market Size Growth (2019-2024)
4.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024)
5.2 Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024)
5.3 Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2019-2024)
6.2 APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024)
6.3 APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Duchenne Muscular Dystrophy Therapeutics by Country (2019-2024)
7.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024)
7.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET FORECAST
10.1 Global Duchenne Muscular Dystrophy Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Duchenne Muscular Dystrophy Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Duchenne Muscular Dystrophy Therapeutics Forecast
10.1.3 APAC Duchenne Muscular Dystrophy Therapeutics Forecast
10.1.4 Europe Duchenne Muscular Dystrophy Therapeutics Forecast
10.1.5 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Forecast
10.2 Americas Duchenne Muscular Dystrophy Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.2.2 Canada Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.2.3 Mexico Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.2.4 Brazil Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3 APAC Duchenne Muscular Dystrophy Therapeutics Forecast by Region (2025-2030)
10.3.1 China Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.2 Japan Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.3 Korea Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.4 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.5 India Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.3.6 Australia Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4 Europe Duchenne Muscular Dystrophy Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4.2 France Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4.3 UK Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4.4 Italy Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.4.5 Russia Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5.2 South Africa Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5.3 Israel Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5.4 Turkey Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.5.5 GCC Countries Duchenne Muscular Dystrophy Therapeutics Market Forecast
10.6 Global Duchenne Muscular Dystrophy Therapeutics Forecast by Type (2025-2030)
10.7 Global Duchenne Muscular Dystrophy Therapeutics Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Offered
11.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Bristol-Myers Squibb Main Business Overview
11.1.5 Bristol-Myers Squibb Latest Developments
11.2 FibroGen (US)
11.2.1 FibroGen (US) Company Information
11.2.2 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 FibroGen (US) Main Business Overview
11.2.5 FibroGen (US) Latest Developments
11.3 Italfarmaco (Italy)
11.3.1 Italfarmaco (Italy) Company Information
11.3.2 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Italfarmaco (Italy) Main Business Overview
11.3.5 Italfarmaco (Italy) Latest Developments
11.4 Marathon
11.4.1 Marathon Company Information
11.4.2 Marathon Duchenne Muscular Dystrophy Therapeutics Product Offered
11.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Marathon Main Business Overview
11.4.5 Marathon Latest Developments
11.5 NS Pharma (US)
11.5.1 NS Pharma (US) Company Information
11.5.2 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 NS Pharma (US) Main Business Overview
11.5.5 NS Pharma (US) Latest Developments
11.6 PTC Therapeutics (US)
11.6.1 PTC Therapeutics (US) Company Information
11.6.2 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 PTC Therapeutics (US) Main Business Overview
11.6.5 PTC Therapeutics (US) Latest Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Duchenne Muscular Dystrophy Therapeutics Product Offered
11.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Pfizer Main Business Overview
11.7.5 Pfizer Latest Developments
11.8 ReveraGen BioPharma (US)
11.8.1 ReveraGen BioPharma (US) Company Information
11.8.2 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 ReveraGen BioPharma (US) Main Business Overview
11.8.5 ReveraGen BioPharma (US) Latest Developments
11.9 Santhera Pharmaceuticals (Switzerland)
11.9.1 Santhera Pharmaceuticals (Switzerland) Company Information
11.9.2 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Santhera Pharmaceuticals (Switzerland) Main Business Overview
11.9.5 Santhera Pharmaceuticals (Switzerland) Latest Developments
11.10 Sarepta Therapeutics (US)
11.10.1 Sarepta Therapeutics (US) Company Information
11.10.2 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
11.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Sarepta Therapeutics (US) Main Business Overview
11.10.5 Sarepta Therapeutics (US) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Pain Management Drugs
Table 3. Major Players of Corticosteroids
Table 4. Major Players of Prednisolone
Table 5. Major Players of Prednisone
Table 6. Major Players of Deflazacort
Table 7. Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 9. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 10. Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 11. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 12. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 13. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 14. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Player (2019-2024)
Table 15. Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Products Offered
Table 16. Duchenne Muscular Dystrophy Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 20. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Regions (2019-2024)
Table 21. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 22. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 23. Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 24. Americas Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Country (2019-2024)
Table 25. Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 26. Americas Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 27. Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 28. Americas Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 29. APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 30. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Region (2019-2024)
Table 31. APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 32. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 33. APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 34. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 35. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 36. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Country (2019-2024)
Table 37. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 38. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 39. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 40. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 41. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Region (2019-2024)
Table 43. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 45. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 46. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 47. Key Market Drivers & Growth Opportunities of Duchenne Muscular Dystrophy Therapeutics
Table 48. Key Market Challenges & Risks of Duchenne Muscular Dystrophy Therapeutics
Table 49. Key Industry Trends of Duchenne Muscular Dystrophy Therapeutics
Table 50. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 51. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 52. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 53. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 54. Bristol-Myers Squibb Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 55. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 56. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 57. Bristol-Myers Squibb Main Business
Table 58. Bristol-Myers Squibb Latest Developments
Table 59. FibroGen (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 60. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 61. FibroGen (US) Main Business
Table 62. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. FibroGen (US) Latest Developments
Table 64. Italfarmaco (Italy) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 65. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 66. Italfarmaco (Italy) Main Business
Table 67. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. Italfarmaco (Italy) Latest Developments
Table 69. Marathon Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 70. Marathon Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 71. Marathon Main Business
Table 72. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. Marathon Latest Developments
Table 74. NS Pharma (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 75. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 76. NS Pharma (US) Main Business
Table 77. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. NS Pharma (US) Latest Developments
Table 79. PTC Therapeutics (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 80. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 81. PTC Therapeutics (US) Main Business
Table 82. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. PTC Therapeutics (US) Latest Developments
Table 84. Pfizer Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 85. Pfizer Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 86. Pfizer Main Business
Table 87. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. Pfizer Latest Developments
Table 89. ReveraGen BioPharma (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 90. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 91. ReveraGen BioPharma (US) Main Business
Table 92. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. ReveraGen BioPharma (US) Latest Developments
Table 94. Santhera Pharmaceuticals (Switzerland) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 95. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 96. Santhera Pharmaceuticals (Switzerland) Main Business
Table 97. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 98. Santhera Pharmaceuticals (Switzerland) Latest Developments
Table 99. Sarepta Therapeutics (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 100. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 101. Sarepta Therapeutics (US) Main Business
Table 102. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 103. Sarepta Therapeutics (US) Latest Developments
Table 1. Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Pain Management Drugs
Table 3. Major Players of Corticosteroids
Table 4. Major Players of Prednisolone
Table 5. Major Players of Prednisone
Table 6. Major Players of Deflazacort
Table 7. Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 8. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 9. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 10. Duchenne Muscular Dystrophy Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 11. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 12. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 13. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Players (2019-2024) & ($ Millions)
Table 14. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Player (2019-2024)
Table 15. Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Products Offered
Table 16. Duchenne Muscular Dystrophy Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Regions 2019-2024 & ($ Millions)
Table 20. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Regions (2019-2024)
Table 21. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Country/Region (2019-2024) & ($ millions)
Table 22. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Country/Region (2019-2024)
Table 23. Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 24. Americas Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Country (2019-2024)
Table 25. Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 26. Americas Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 27. Americas Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 28. Americas Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 29. APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 30. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Region (2019-2024)
Table 31. APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 32. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 33. APAC Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 34. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 35. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2019-2024) & ($ Millions)
Table 36. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Country (2019-2024)
Table 37. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 38. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 39. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 40. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 41. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Region (2019-2024)
Table 43. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Table 45. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2019-2024) & ($ Millions)
Table 46. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Table 47. Key Market Drivers & Growth Opportunities of Duchenne Muscular Dystrophy Therapeutics
Table 48. Key Market Challenges & Risks of Duchenne Muscular Dystrophy Therapeutics
Table 49. Key Industry Trends of Duchenne Muscular Dystrophy Therapeutics
Table 50. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 51. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share Forecast by Regions (2025-2030)
Table 52. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 53. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 54. Bristol-Myers Squibb Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 55. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 56. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 57. Bristol-Myers Squibb Main Business
Table 58. Bristol-Myers Squibb Latest Developments
Table 59. FibroGen (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 60. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 61. FibroGen (US) Main Business
Table 62. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 63. FibroGen (US) Latest Developments
Table 64. Italfarmaco (Italy) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 65. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 66. Italfarmaco (Italy) Main Business
Table 67. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 68. Italfarmaco (Italy) Latest Developments
Table 69. Marathon Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 70. Marathon Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 71. Marathon Main Business
Table 72. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 73. Marathon Latest Developments
Table 74. NS Pharma (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 75. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 76. NS Pharma (US) Main Business
Table 77. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 78. NS Pharma (US) Latest Developments
Table 79. PTC Therapeutics (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 80. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 81. PTC Therapeutics (US) Main Business
Table 82. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 83. PTC Therapeutics (US) Latest Developments
Table 84. Pfizer Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 85. Pfizer Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 86. Pfizer Main Business
Table 87. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 88. Pfizer Latest Developments
Table 89. ReveraGen BioPharma (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 90. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 91. ReveraGen BioPharma (US) Main Business
Table 92. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 93. ReveraGen BioPharma (US) Latest Developments
Table 94. Santhera Pharmaceuticals (Switzerland) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 95. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 96. Santhera Pharmaceuticals (Switzerland) Main Business
Table 97. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 98. Santhera Pharmaceuticals (Switzerland) Latest Developments
Table 99. Sarepta Therapeutics (US) Details, Company Type, Duchenne Muscular Dystrophy Therapeutics Area Served and Its Competitors
Table 100. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offered
Table 101. Sarepta Therapeutics (US) Main Business
Table 102. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 103. Sarepta Therapeutics (US) Latest Developments
LIST OF FIGURES
Figure 1. Duchenne Muscular Dystrophy Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Duchenne Muscular Dystrophy Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type in 2023
Figure 10. Duchenne Muscular Dystrophy Therapeutics in Hospitals
Figure 11. Global Duchenne Muscular Dystrophy Therapeutics Market: Hospitals (2019-2024) & ($ Millions)
Figure 12. Duchenne Muscular Dystrophy Therapeutics in Clinics
Figure 13. Global Duchenne Muscular Dystrophy Therapeutics Market: Clinics (2019-2024) & ($ Millions)
Figure 14. Duchenne Muscular Dystrophy Therapeutics in Home Care
Figure 15. Global Duchenne Muscular Dystrophy Therapeutics Market: Home Care (2019-2024) & ($ Millions)
Figure 16. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application in 2023
Figure 17. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Player in 2023
Figure 18. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2024 ($ Millions)
Figure 20. APAC Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2024 ($ Millions)
Figure 21. Europe Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2024 ($ Millions)
Figure 23. Americas Duchenne Muscular Dystrophy Therapeutics Value Market Share by Country in 2023
Figure 24. United States Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Region in 2023
Figure 29. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type in 2023
Figure 30. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application in 2023
Figure 31. China Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Country in 2023
Figure 38. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Figure 39. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Figure 40. Germany Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 54. APAC Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 55. Europe Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. United States Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Canada Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. China Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Japan Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. Korea Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. India Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. Australia Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. Germany Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. France Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. UK Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. Italy Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. Russia Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. Spain Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. Israel Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 78. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Duchenne Muscular Dystrophy Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Duchenne Muscular Dystrophy Therapeutics Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Country/Region (2023)
Figure 8. Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type in 2023
Figure 10. Duchenne Muscular Dystrophy Therapeutics in Hospitals
Figure 11. Global Duchenne Muscular Dystrophy Therapeutics Market: Hospitals (2019-2024) & ($ Millions)
Figure 12. Duchenne Muscular Dystrophy Therapeutics in Clinics
Figure 13. Global Duchenne Muscular Dystrophy Therapeutics Market: Clinics (2019-2024) & ($ Millions)
Figure 14. Duchenne Muscular Dystrophy Therapeutics in Home Care
Figure 15. Global Duchenne Muscular Dystrophy Therapeutics Market: Home Care (2019-2024) & ($ Millions)
Figure 16. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application in 2023
Figure 17. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Player in 2023
Figure 18. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2024 ($ Millions)
Figure 20. APAC Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2024 ($ Millions)
Figure 21. Europe Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size 2019-2024 ($ Millions)
Figure 23. Americas Duchenne Muscular Dystrophy Therapeutics Value Market Share by Country in 2023
Figure 24. United States Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Region in 2023
Figure 29. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type in 2023
Figure 30. APAC Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application in 2023
Figure 31. China Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Country in 2023
Figure 38. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Figure 39. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Figure 40. Germany Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Duchenne Muscular Dystrophy Therapeutics Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 54. APAC Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 55. Europe Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 57. United States Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 58. Canada Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 61. China Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 62. Japan Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 63. Korea Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 65. India Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 66. Australia Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 67. Germany Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 68. France Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 69. UK Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 70. Italy Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 71. Russia Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 72. Spain Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 75. Israel Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Duchenne Muscular Dystrophy Therapeutics Market Size 2025-2030 ($ Millions)
Figure 78. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share Forecast by Application (2025-2030)
